A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes

• Status: RECRUITING
• Trial end date: 2026-10-01

Summary

This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2 diabetes.

• Phase: PHASE4

Details

• Lead Sponsor: Boryung Pharmaceutical Co., Ltd
• Treatments: dapagliflozin; Metformin; Pioglitazone; Sitagliptin Phosphate